Request Clinical Starter Kits for Your Patients Today! Request Now

 Niacinamide Research (including Wax Matrix) STUDIES

Pharmacokinetic profile of ENDUR-AMIDE® sustained-release niacinamide

Highlights Sustained-release ENDUR-AMIDE® and standard niacinamide pharmacokinetics studied in young men Low-dose preparations yield similar results High-dose preparations differ in several parameters (Cmax, AUC and Tmax) Summary The aim of...
on August 29, 2020

Niacin may reduce apoptosis, preclinical study shows

Highlights Nicotinic acid & niacinamide exert anti-apoptotic action Action appears to be multifactorial, including DNA repair Action appears unrelated to reducing oxidative stress Summary The aim of this in-vitro study...
on August 29, 2020

The Effect of ENDUR-AMIDE® on Type 1 Diabetes Prevention in School Children: An 8-Year Study

Highlights ENDUR-AMIDE® may help delay the onset of type 1 diabetes in young children. Treatment dosage was 500 mg, twice daily Excellent compliance (over 90%) with treatment Summary This clinical...
on February 25, 2020

Niacinamide supplementation reduces nonmelanoma skin cancers in high-risk patients, study shows

Highlights Niacinamide reduces incidence of nonmelanoma skin cancers in high-risk patients 23% reduction in new nonmelanoma skin cancers at 12 months 13% reduction in the number of actinic keratoses at...
on February 25, 2020

Niacinamide supplementation reduces actinic keratoses in adults with sun damage, studies shows

Highlights Niacinamide reduces incidence of actinic keratoses (AK) in adults with sun damage AK is a strong predictor of non-melanoma skin cancer AK count reduced by 29% to 35% with...
on February 25, 2020
"